Results 1 to 10 of about 316,072 (161)

Newer anti-vascular endothelial growth factor agents

TNOA Journal of Ophthalmic Science and Research, 2020
Ocular angiogenesis is a major cause of ocular morbidity worldwide. Vascular endothelial growth factor (VEGF) is a critical regulator of angiogenesis and vascular permeability with diverse roles both during the development and adulthood. This is believed
Priya Rasipuram Chandrasekaran
doaj   +2 more sources

Anti-vascular endothelial growth factor therapies in ophthalmology. [PDF]

Med Hypothesis Discov Innov Ophthalmol
Background: Retinal diseases, including neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, are leading causes of vision loss worldwide. The introduction of anti-vascular endothelial growth factor (anti-VEGF) therapies has dramatically changed the management of these conditions, offering targeted treatment ...
Koksaldi S, Karti O, Saatci AO.
europepmc   +3 more sources

Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders [PDF]

Pharmaceuticals, 2023
Vascular endothelial growth factors (VEGFs) are key mediator of retinal and choroidal neovascularization as well as retinal vascular leakage leading to macular edema.
Abraham Hang, Samuel Feldman, Aana P. Amin, Jorge A. Rivas Ochoa, Susanna S. Park   +4 more
doaj   +4 more sources

Anti-vascular endothelial growth factor treatment in diabetic macular edema

Therapeutics and Clinical Risk Management, 2016
Moosang KimDepartment of Ophthalmology, School of Medicine, Kangwon National University, Chuncheon, KoreaWe read with great interest the article titled “Clinical effects and safety of treating diabetic macular edema with intravitreal injection of ...
Kim M
doaj   +4 more sources

Low-fluence PDT better than anti-vascular endothelial growth factor

Indian Journal of Ophthalmology, 2013
Sir, It was interesting to read the article “Low-fluence photodynamic therapy” for early onset choroidal neovascular membrane (CNVM) following LASIK by Dr. George J Manayath et al.[1] The authors have to be commended for an excellent work. But I have some reservations that I would like to state. Were there any pathological myopia changes recorded
K S Santhan Gopal
doaj   +3 more sources

Anti-vascular endothelial growth factor in ophthalmology

Indian Journal of Ophthalmology, 2009
Sinha Rajesh, Choudhary Sunil, Sinha Subijoy, Vashisht Nagender, Kumar Chandrashekhar   +4 more
doaj   +2 more sources

Anti-vascular endothelial growth factor for neovascular glaucoma [PDF]

Cochrane Database of Systematic Reviews, 2009
Neovascular glaucoma (NVG) is a potentially blinding secondary glaucoma. It is caused by the formation of abnormal new blood vessels which prevent normal drainage of aqueous from the anterior segment of the eye. Anti-vascular endothelial growth factor (anti-VEGF) agents are specific inhibitors of the primary mediators of neovascularization.
Arathi, Simha, Andrew, Braganza, Lekha, Abraham, Prasanna, Samuel, Kristina, Lindsley   +4 more
openaire   +4 more sources

Biomarkers for anti‑vascular endothelial growth factor drugs

Oncology Letters, 2022
Angiogenesis is regulated by interactions between vascular endothelial growth factors (VEGFs) and VEGF receptors. VEGF-A, VEGF-D, placental growth factor (PlGF) and plasminogen activator inhibitor-1 (PAI-1) have tumor angiogenic activity. VEGF-A and PAI-1 levels in the blood may impact the activity of bevacizumab, and VEGF-D levels may similarly ...
Kuriyama, Sho, Yamada, Takeshi, Matsuda, Akihisa, Takahashi, Goro, Iwai, Takuma, Takeda, Kohki, Ueda, Koji, Miyasaka, Toshimitsu, Yokoyama, Yasuyuki, Shinji, Seiichi, Sonoda, Hiromichi, Ohta, Ryo, Yonaga, Kazuhide, Kanaka, Shintaro, Yoshida, Hiroshi   +14 more
openaire   +2 more sources

ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY

Retina, 2022
Background/Purpose: Anti–vascular endothelial growth factor therapies have proven effective in treating retinal diseases but come with a high financial burden to the patient and health care system. Biosimilar drugs present an opportunity to decrease the cost of these important ophthalmic medications, and several ophthalmic ...
Kaiser, Peter K., Schmitz-Valckenberg, Marc Steffen, Holz, Frank G.   +2 more
openaire   +2 more sources

Anti-vascular endothelial growth factor for proliferative diabetic retinopathy

Cochrane Database of Systematic Reviews, 2023
Proliferative diabetic retinopathy (PDR) is an advanced complication of diabetic retinopathy that can cause blindness. It consists of the presence of new vessels in the retina and vitreous haemorrhage. Although panretinal photocoagulation (PRP) is the treatment of choice for PDR, it has secondary effects that can affect vision.
Martinez-Zapata M. J., Salvador I., Marti-Carvajal A. J., Pijoan J. I., Cordero J. A., Ponomarev D., Kernohan A., Sola I., Virgili G.   +8 more
openaire   +5 more sources